We are live on ! Find out more
CM

CM Management Portfolio holdings

AUM $120M
1-Year Est. Return 37.12%
This Fund
S&P 500
This Quarter Est. Return
+2.85%
1 Year Est. Return
+37.12%
3 Year Est. Return
+141.34%
5 Year Est. Return
+139.46%
10 Year Est. Return
–
AUM
$138M
AUM Growth
+$3.81M
Cap. Flow
+$4.2M
Cap. Flow %
3.03%
Top 10 Hldgs %
35.89%
Holding
98
New
17
Increased
24
Reduced
4
Closed
13

Top Buys

Rank Stock Value
1
AVIR icon
Atea Pharmaceuticals
AVIR
+$2.7M
2
CTRA
Coterra Energy
CTRA
+$2.04M
3
BP icon
BP
BP
+$1.57M
4
INTC icon
Intel
INTC
+$1.47M
5
C icon
Citigroup
C
+$1.18M

Top Sells

Rank Stock Value
1
INTT icon
inTEST
INTT
+$2.95M
2
MRK icon
Merck
MRK
+$1.85M
3
EXEL icon
Exelixis
EXEL
+$1.81M
4
SWN
Southwestern Energy Company
SWN
+$1.63M
5
ET icon
Energy Transfer Partners
ET
+$1.54M

Sector Composition

Rank Sector Weight
1 Healthcare 36.58%
2 Financials 14.24%
3 Technology 13.07%
4 Energy 11.74%
5 Materials 7.65%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TRC icon
51
Tejon Ranch
TRC
$476M
$1.06M 0.77%
70,000
– –
ACNB icon
52
ACNB Corp
ACNB
$634M
$949K 0.69%
34,000
– –
CTXS
53
DELISTED
Citrix Systems Inc
CTXS
$938K 0.68%
+8,000
New +$996K
ICPT
54
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$899K 0.65%
+45,000
New +$892K
EQT icon
55
EQT Corp
EQT
$33.2B
$890K 0.64%
40,000
+15,000
+60% +$303K
TVTX icon
56
Travere Therapeutics
TVTX
$5.33B
$875K 0.63%
60,000
+28,000
+88% +$552K
DISCK
57
DELISTED
Discovery, Inc. Series C Common Stock
DISCK
$869K 0.63%
+30,000
New +$932K
NKTR icon
58
Nektar Therapeutics
NKTR
$2.39B
$858K 0.62%
3,333
– –
SMSI icon
59
Smith Micro Software
SMSI
$14M
$835K 0.6%
4,000
– –
MTG icon
60
MGIC Investment
MTG
$6.27B
$816K 0.59%
60,000
– –
USAP
61
DELISTED
Universal Stainless & Alloy
USAP
$795K 0.57%
+78,542
New +$787K
WBA
62
DELISTED
Walgreens Boots Alliance
WBA
$789K 0.57%
+15,000
New +$807K
HRTX icon
63
Heron Therapeutics
HRTX
$86.3M
$776K 0.56%
50,000
– –
ATER icon
64
Aterian
ATER
$4.35M
$732K 0.53%
4,167
+834
+25% +$195K
TBPH icon
65
Theravance Biopharma
TBPH
$874M
$726K 0.52%
50,000
– –
CRTD
66
DELISTED
Creatd Inc. Common Stock
CRTD
$713K 0.52%
190,000
+115,000
+153% +$416K
CBAY
67
DELISTED
Cymabay Therapeutics
CBAY
$654K 0.47%
150,000
– –
FLXN
68
DELISTED
Flexion Therapeutics, Inc.
FLXN
$617K 0.45%
75,000
– –
OGN icon
69
Organon & Co
OGN
$3.55B
$605K 0.44%
+20,000
New +$658K
PLPC icon
70
Preformed Line Products
PLPC
$1.52B
$594K 0.43%
8,000
– –
ELDN icon
71
Eledon Pharmaceuticals
ELDN
$276M
$593K 0.43%
75,000
– –
PAAS icon
72
Pan American Silver
PAAS
$18.6B
$571K 0.41%
+20,000
New +$644K
SRCE icon
73
1st Source
SRCE
$2.07B
$558K 0.4%
12,000
– –
BCEL
74
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$511K 0.37%
60,000
– –
VYNE icon
75
VYNE Therapeutics
VYNE
$17M
$505K 0.37%
7,986
– –
1 2
3
4

Similar funds

CC
Commons Capital Needham, Massachusetts $120M AUM 31.45% 1-Year Est. Return
DG
Dala Group Hoffman Estates, Illinois $120M AUM
ACM
AIHC Capital Management Central $120M AUM
WAG
Windsor Advisory Group Columbus, Ohio $120M AUM 4.29% 1-Year Est. Return
BCWM
Ball & Co Wealth Management Franklin, Tennessee $120M AUM 21.28% 1-Year Est. Return
WF
WealthPoint Financial Cramerton, North Carolina $119M AUM
SA
SJBenen ADVISORY Chapel Hill, North Carolina $120M AUM
SRL
Scientech Research LLC Jersey City, New Jersey $120M AUM 73.62% 1-Year Est. Return

CM Management's Q2 2021 Portfolio in Review

As of Q2 2021, CM Management held 98 positions worth $138M, up 2.8% from $135M the previous quarter. Its ten largest holdings account for 36% of the portfolio.

CM Management deployed $4.2M of net new capital in Q2 2021, opening 17 new positions and adding to 24 existing holdings. Its largest new stake was Atea Pharmaceuticals: 90,000 shares worth $1.93M.

By sector, the portfolio is most concentrated in Healthcare at 37% of assets, down from 41% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was inTEST, an estimated $2.95M trimmed.

  • CM Management's largest Q2 2021 buy was Atea Pharmaceuticals: 90,000 shares worth $1.93M.
  • CM Management added most to Coterra Energy in Q2 2021, an estimated $2.04M increase.
  • CM Management's biggest Q2 2021 reduction was inTEST, cutting an estimated $2.95M.
  • CM Management fully exited Merck in Q2 2021, selling an estimated $1.85M.
  • CM Management's ten largest holdings make up 36% of its $138M portfolio in Q2 2021.
  • CM Management opened 17 new positions and closed 13 in Q2 2021.
  • CM Management's portfolio value rose 2.8% quarter-over-quarter to $138M.

Based on CM Management's 13F filing for Q2 2021, filed 10 Aug 2021.